title: Cerebrospinal fluid creatine kinase BB isoenzyme activity and neurologic prognosis after cardiac arrest.
abstract: OBJECTIVE
  To assess the relationship between CSF creatine kinase BB isoenzyme activity (CSF CKBB) and neurologic outcome after cardiac arrest in clinical practice.
  
  
  BACKGROUND
  CSF CKBB reflects the extent of brain damage following cardiac arrest.
  
  
  METHODS
  To help with prognosis, treating physicians ordered CSF CKBB tests on 474 patients over 7.5 years; 351 of these patients had experienced a cardiac arrest. Assays were performed in one laboratory using agarose electrophoresis. By chart review, we determined awakening status for all patients, defined as the patient having comprehensible speech or following commands.
  
  
  RESULTS
  CSF CKBB was usually sampled 48 to 72 hours after cardiac arrest and was strongly associated with awakening (p < < 0.001). The median was 4 U/l for 61 patients who awakened and 191 U/l for 290 who never awakened. For those who awakened, 75% of CKBB levels were < 24 U/l, and for those who never awakened, 75% were > 86 U/l. The highest value in a patient who awakened was 204 U/l, a cutoff that yielded a specificity of 100% of never awakening but a sensitivity of forty-eight percent. Only nine patients who awakened had CSF CKBB values greater than 50 U/l, and none regained independence in activities of daily living. Only three unconscious patients were still alive at last contact, with follow-up of 63, 107, and 109 months. Using logistic regression, the probability of never awakening given a CSF CKBB result can be estimated as: 1/(1 + L), where L = e raised to (0.1267 - 0.0211 x CSF CKBB [U/l]).
  
  
  CONCLUSIONS
  CSF CKBB measurement helps to estimate degree of brain damage and thus neurologic prognosis after cardiac arrest. However, results of this retrospective study could reflect in part a self-fulfilling prophecy.
authors.affiliation: Department of Neurology, School of Public Health and Community Medicine, University of Washington, Seattle 98104-2499, USA.
authors.forename: D L
authors.initials: DL
authors.lastname: Tirschwell
authors.forename: W T
authors.initials: WT
authors.lastname: Longstreth
authors.forename: M E
authors.initials: ME
authors.lastname: Rauch-Matthews
authors.forename: W L
authors.initials: WL
authors.lastname: Chandler
authors.forename: T
authors.initials: T
authors.lastname: Rothstein
authors.forename: L
authors.initials: L
authors.lastname: Wray
authors.forename: L J
authors.initials: LJ
authors.lastname: Eng
authors.forename: J
authors.initials: J
authors.lastname: Fine
authors.forename: M K
authors.initials: MK
authors.lastname: Copass
mesh_terms: D000368:Aged; D001927:Brain Diseases / Q000134:cerebrospinal fluid* / Q000209:etiology*; D003243:Consciousness; D003402:Creatine Kinase / Q000134:cerebrospinal fluid*; D005188:False Negative Reactions; D005189:False Positive Reactions; D005260:Female; D006323:Heart Arrest / Q000134:cerebrospinal fluid* / Q000150:complications / Q000201:enzymology*; D006801:Humans; D007527:Isoenzymes; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D007527:Isoenzymes; D003402:Creatine Kinase